RxDoctor Payments DataLook up a doctor →

Jessica Cuevas Rosas, PA

Psychiatric/Mental Health · Long Beach, CANPI 1942809009

Payments from drug & device makers

$23,316in general payments, 2019–2025

Across 1,058 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Vanda Pharmaceuticals Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • plus $10K from 36 others

What the payments were for

  • Food & beverage$23,19399%
  • Education$1231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,316 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$17,819
Medicare patients
25
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl24$35,919
Lurasidone Hcl35$33,923
RexultiBrexpiprazole13$19,318
TrintellixVortioxetine Hydrobromide21$11,210
Bupropion XlBupropion Hcl54$1,444
Aripiprazole18$1,428
Armodafinil14$1,172
Trazodone Hcl61$612
Fluoxetine Hcl27$526
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine28$473
Buspirone Hcl33$431
Venlafaxine Hcl ErVenlafaxine Hcl30$418
Prazosin Hcl23$370
Gabapentin29$299
Clonazepam59$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$3,560$35,91924 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,956$19,31813 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$523$11,21021 claims
Almatica Pharma LLCSertraline Hcl$33$9819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →